What is Royalty Pharma's goodwill?

Royalty Pharma (RPRX) reported goodwill of $924.63M in Q1 2026.

What does goodwill mean?

The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.

Royalty Pharma RPRX Goodwill

Goodwill at other companies

Ligand PharmaceuticalsLGND

$101.54M0.0%

Rigel PharmaceuticalsRIGL

$24.16M-8.9%

Bristol-Myers SquibbBMY

$21.74B-0.2%

Ultragenyx PharmaceuticalRARE

$44M-0.9%

Innoviva, Inc.INVA

$17.91M0.0%

AbbVieABBV

$35.57B+0.8%

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's goodwill?: Royalty Pharma (RPRX) reported goodwill of $924.63M in Q1 2026.
What does goodwill mean?: The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.